
BMS says Phase III trials for Opdivo show improved overall survival in lung cancer
pharmafile | May 19, 2016 | News story | Research and Development | Bristol-Myers Squibb, drug trial, lung cancer, opdivo
Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the two-year time point.
The trials were to evaluate overall survival via two pivotal Phase III studies versus docetaxel in previously treated metastatic non-small cell lung cancer (NSCLC). In addition, the safety profile of Opdivo at two years was consistent with previous reports of data from both studies.
Hossein Borghaei, chief, Thoracic Oncology, Fox Chase Cancer Center, said: “Data presented at ASCO underscore the potential of Opdivo to improve long-term outcomes for patients with this particularly challenging disease.”
Nick Botwood development lead, Lung and Head & Neck, Bristol-Myers Squibb, said: “Today, these data from CheckMate -057 and -017 expand our understanding of the potential for Opdivo to provide a meaningful, durable survival benefit to patients with previously treated metastatic NSCLC.”
Anjali Shukla
Related Content

HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …

Graphene-based biosensor to support new lung cancer screening test
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …

FDA approves diagnostic tool for MET-targeted lung cancer therapy
The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay …






